Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.66 |
| ▸ | RAF1 | P04049 | 4/20 | 0.53 |
| ▸ | BRAF | P15056 | 4/20 | 0.53 |
| ▸ | KDR | P35968 | 8/20 | 0.49 |
| ▸ | SRC | P12931 | 5/20 | 0.49 |
| ▸ | RET | P07949 | 2/20 | 0.48 |
| ▸ | CSK | P41240 | 1/20 | 0.45 |
| ▸ | TEK | Q02763 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21751025 | 0.94 | EGFR (0.59) | EGFRRAF1BRAFKDRSRC | |
| SCHEMBL21750822 | 0.92 | EGFR (0.57) | EGFRRAF1BRAFKDRSRC | |
| SCHEMBL21751017 | 0.91 | EGFR (0.56) | EGFRRAF1BRAFKDRSRC | |
| SCHEMBL30664575 | 0.91 | EGFR (0.56) | EGFRRAF1BRAFKDRSRC | |
| SCHEMBL21750912 | 0.90 | EGFR (0.55) | EGFRRAF1BRAFKDRSRC | |
| SCHEMBL21751009 | 0.87 | EGFR (0.53) | EGFRRAF1BRAFKDRSRC | |
| SCHEMBL21750920 | 0.86 | EGFR (0.51) | EGFRRAF1BRAFKDRSRC | |
| SCHEMBL30664552 | 0.86 | EGFR (0.51) | EGFRRAF1BRAFKDRSRC | |
| SCHEMBL21750921 | 0.84 | KDR (0.55) | EGFRRAF1BRAFKDRSRC | |
| SCHEMBL21265407 | 0.83 | EGFR (0.61) | EGFRRAF1BRAFKDRSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12202835-B2 | Substituted aromatic ring-linked dioxinoquinazolines and dioxinoquinolines as kinase inhibitors | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2025-01-21 | — | — | US | disclosed |
| EP-3590941-B1 | UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXANE-QUINAZOLINE AND -LINKED DIOXANE-QUINOLINE COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-11-22 | — | — | EP | disclosed |
| EP-3590941-B1 | UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXANE-QUINAZOLINE AND -LINKED DIOXANE-QUINOLINE COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-11-22 | — | — | EP | disclosed |
| US-20220002308-A1 | AROMATIC RING-LINKED DIOXINO-QUINAZOLINE OR DIOXINO-QUINOLINE COMPOUNDS, COMPOSITIONS AND USE THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2022-01-06 | — | — | US | disclosed |
| EP-3865487-A1 | AROMATIC RING-LINKED DIOXANE-QUINAZOLINE OR -QUINOLINE COMPOUNDS, COMPOSITIONS AND USE THEREOF | Beijing Scitech-MQ Pharmaceuticals Limited (CN) | 2021-08-18 | — | — | EP | disclosed |
| EP-3865487-A1 | AROMATIC RING-LINKED DIOXANE-QUINAZOLINE OR -QUINOLINE COMPOUNDS, COMPOSITIONS AND USE THEREOF | Beijing Scitech-MQ Pharmaceuticals Limited (CN) | 2021-08-18 | — | — | EP | disclosed |
| US-10980809-B2 | Urea-substituted aromatic ring-linked dioxane-quinazoline and -linked dioxane-quinoline compounds, preparation method therefor and use thereof | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2021-04-20 | — | — | US | disclosed |
| US-10980809-B2 | Urea-substituted aromatic ring-linked dioxane-quinazoline and -linked dioxane-quinoline compounds, preparation method therefor and use thereof | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2021-04-20 | — | — | US | disclosed |
| WO-2020042972-A1 | UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXANE AND QUINAZOLINE OR QUINOLINE COMPOUND, COMPOSITION AND APPLICATION THEREOF | 北京赛特明强医药科技有限公司 | 2020-03-05 | — | — | WO | disclosed |
| US-20200061065-A1 | UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXANE-QUINAZOLINE AND -LINKED DIOXANE-QUINOLINE COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2020-02-27 | — | — | US | disclosed |
| US-20200061065-A1 | UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXANE-QUINAZOLINE AND -LINKED DIOXANE-QUINOLINE COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200061065-A1 | UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXANE-QUINAZOLINE AND -LINKED DIOXANE-QUINOLINE COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | BRAF, RAF1, ARAF | EGFR 363/4885RAF1 2/4885BRAF 1/4885 |
| US-10980809-B2 | Urea-substituted aromatic ring-linked dioxane-quinazoline and -linked dioxane-quinoline compounds, preparation method therefor and use thereof | BRAF, RAF1, ARAF | EGFR 363/4885RAF1 2/4885BRAF 1/4885 |
| US-20220002308-A1 | AROMATIC RING-LINKED DIOXINO-QUINAZOLINE OR DIOXINO-QUINOLINE COMPOUNDS, COMPOSITIONS AND USE THEREOF | MERTK, AXL, TYRO3 | EGFR 58/4885RAF1 19/4885BRAF 12/4885 |
| US-12202835-B2 | Substituted aromatic ring-linked dioxinoquinazolines and dioxinoquinolines as kinase inhibitors | MERTK, AXL, TYRO3 | EGFR 50/4885RAF1 27/4885BRAF 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.